Srinivasan Madhusudan

Contact

• workBiodiscovery Institute, School of Medicine, University of Nottingham
  University Park
  Nottingham
  NG7 2RD
  UK
• work01158231850
• fax01158231849
• srinivasan.madhusudan@nottingham.ac.uk

Biography

Professor Srinivasan Madhusudan trained in Medical Oncology at Oxford, England. As a Cancer Research UK Clinical Research Fellow he completed his Ph.D. work at the Weatherall Institute of Molecular Medicine, Oxford. In 2007, he moved to Nottingham as a Clinical Associate Professor in Medical Oncology. In 2011, he was awarded the prestigious 'Goulstonian Lectureship' by the Royal College of Physicians, London, an award made to the most academically outstanding Young Fellow of the College. In 2016, he was promoted to Professor of Medical Oncology. He served as the Head of Oncology at Nottingham University Hospitals from 2017-2020. As an academic oncologist, he is very active in cancer clinical trials. He has lead the Cancer Clinical Trials Unit at Nottingham University Hospitals and was previously the National Institute for Health Research (NIHR) Divisional Lead for Cancer (East Midlands).

Prof Madhusudan's Clinical Research expertise is in breast, upper GI and ovarian cancers. His pre-clinical laboratory research is focused on the evaluation of DNA damage signaling and repair in cancer. He is the Director of the Nottingham Ovarian Cancer Research Centre (NOVARC) based at the Biodiscovery Institute. He is an active member of the Nottingham Breast Cancer Research Centre (NBCRC). Research in his laboratory has received funding from the Medical Research Council, Breast Cancer Now, Target Ovarian Cancer and Naaz-Coker Ovarian Cancer Research Fellowship. Graduate Research students in his group are funded through various international scholarships. Prof Madhusudan's group has identified novel biomarkers, potential drug targets and newer approaches for personalized treatment strategies targeting DNA repair in cancer. Prof Madhusudan has published over 150 research articles, edited two books and contributed to several book chapters. In recognition of his outstanding translational cancer research, he was recently awarded the prestigious 'Lady Estelle Wolfson lectureship in Translational Medicine for 2019' by the Royal College of Physicians of London.

Expertise Summary

Clinical trials; DNA repair; translational oncology; biomarkers; drug discovery; breast cancers; upper GI cancers; ovarian cancers.

Research Summary

DNA repair targeted precision medicine strategies in cancers.

Selected Publications

• HURVITZ, S. A., HEGG, R., CHUNG, W. P., IM, S. A., JACOT, W., GANJU, V., CHIU, J. W. Y., XU, B., HAMILTON, E., MADHUSUDAN, S., IWATA, H., ALTINTAS, S., HENNING, J. W., CURIGLIANO, G., PEREZ-GARCIA, J. M., KIM, S. B., PETRY, V., HUANG, C. S., LI, W., FRENEL, J. S., ANTOLIN, S., YEO, W., BIANCHINI, G., LOI, S., TSURUTANI, J., EGOROV, A., LIU, Y., CATHCART, J., ASHFAQUE, S. and CORTES, J., 2023. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial: Lancet Lancet. 401(10371), 105-117
• ALGETHAMI, M., TOSS, M. S., WOODCOCK, C. L., JAIPAL, C., BROWNLIE, J., SHOQAFI, A., ALBLIHY, A., MESQUITA, K. A., GREEN, A. R., MONGAN, N. P., JEYAPALAN, J. N., RAKHA, E. A. and MADHUSUDAN, S., 2023. Unravelling the clinicopathological and functional significance of replication protein A (RPA) heterotrimeric complex in breast cancers: NPJ Breast Cancer NPJ Breast Cancer. 9(1), 18
• TANG, H., KULKARNI, S., PETERS, C., EDDISON, J., AL-ANI, M. and MADHUSUDAN, S., 2023. The Current Status of DNA-Repair-Directed Precision Oncology Strategies in Epithelial Ovarian Cancers: Int J Mol Sci Int J Mol Sci. 24(8),
• ALBLIHY, A., ALI, R., ALGETHAMI, M., SHOQAFI, A., TOSS, M. S., BROWNLIE, J., TATUM, N. J., HICKSON, I., MORAN, P. O., GRABOWSKA, A., JEYAPALAN, J. N., MONGAN, N. P., RAKHA, E. A. and MADHUSUDAN, S., 2022. Targeting Mre11 overcomes platinum resistance and induces synthetic lethality in XRCC1 deficient epithelial ovarian cancers: NPJ Precis Oncol NPJ Precis Oncol. 6(1), 51

• View all publications

Past Research

DNA repair targeted precision medicine strategies in cancers.

Future Research

DNA repair targeted precision medicine strategies in cancers.

• TANG, H., KULKARNI, S., PETERS, C., EDDISON, J., AL-ANI, M. and MADHUSUDAN, S., 2023. The Current Status of DNA-Repair-Directed Precision Oncology Strategies in Epithelial Ovarian Cancers: Int J Mol Sci Int J Mol Sci. 24(8),
• METZLER, V. M., DE BROT, S., HAIGH, D. B., WOODCOCK, C. L., LOTHION-ROY, J., HARRIS, A. E., NILSSON, E. M., NTEKIM, A., PERSSON, J. L., ROBINSON, B. D., KHANI, F., LAURSEN, K. B., GUDAS, L. J., TOSS, M. S., MADHUSUDAN, S., RAKHA, E., HEERY, D. M., RUTLAND, C. S., MONGAN, N. P. and JEYAPALAN, J. N., 2023. The KDM5B and KDM1A lysine demethylases cooperate in regulating androgen receptor expression and signalling in prostate cancer: Front Cell Dev Biol Front Cell Dev Biol. 11, 1116424
• LASHEN, A. G., TOSS, M. S., WOOTTON, L., GREEN, A. R., MONGAN, N. P., MADHUSUDAN, S. and RAKHA, E., 2023. Characteristics and prognostic significance of polo-like kinase-1 (PLK1) expression in breast cancer: Histopathology Histopathology.
• LASHEN, A., TOSS, M. S., FADHIL, W., ONI, G., MADHUSUDAN, S. and RAKHA, E., 2023. Evaluation oncotype DX((R)) 21-gene recurrence score and clinicopathological parameters: a single institutional experience: Histopathology Histopathology. 82(5), 755-766
• HURVITZ, S. A., HEGG, R., CHUNG, W. P., IM, S. A., JACOT, W., GANJU, V., CHIU, J. W. Y., XU, B., HAMILTON, E., MADHUSUDAN, S., IWATA, H., ALTINTAS, S., HENNING, J. W., CURIGLIANO, G., PEREZ-GARCIA, J. M., KIM, S. B., PETRY, V., HUANG, C. S., LI, W., FRENEL, J. S., ANTOLIN, S., YEO, W., BIANCHINI, G., LOI, S., TSURUTANI, J., EGOROV, A., LIU, Y., CATHCART, J., ASHFAQUE, S. and CORTES, J., 2023. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial: Lancet Lancet. 401(10371), 105-117
• BROWNLIE, J., KULKARNI, S., ALGETHAMI, M., JEYAPALAN, J. N., MONGAN, N. P., RAKHA, E. A. and MADHUSUDAN, S., 2023. Targeting DNA damage repair precision medicine strategies in cancer: Curr Opin Pharmacol Curr Opin Pharmacol. 70, 102381
• ALGETHAMI, M., TOSS, M. S., WOODCOCK, C. L., JAIPAL, C., BROWNLIE, J., SHOQAFI, A., ALBLIHY, A., MESQUITA, K. A., GREEN, A. R., MONGAN, N. P., JEYAPALAN, J. N., RAKHA, E. A. and MADHUSUDAN, S., 2023. Unravelling the clinicopathological and functional significance of replication protein A (RPA) heterotrimeric complex in breast cancers: NPJ Breast Cancer NPJ Breast Cancer. 9(1), 18
• MAHMOODI, A., SHOQAFI, A., SUN, P., GIANNAKEAS, V., CYBULSKI, C., NOFECH-MOZES, S., MASSON, J. Y., SHARMA, S., SAMANI, A. A., MADHUSUDAN, S., NAROD, S. A. and AKBARI, M. R., 2022. High Expression of RECQL Protein in ER-Positive Breast Tumours Is Associated With a Better Survival: Front Oncol Front Oncol. 12, 877617
• LOTHION-ROY, J., HAIGH, D. B., HARRIS, A. E., METZLER, V. M., ALSALEEM, M., TOSS, M. S., KARIRI, Y., NTEKIM, A., ROBINSON, B. D., KHANI, F., GUDAS, L. J., ALLEGRUCCI, C., JAMES, V. H., MADHUSUDAN, S., MATHER, M., EMES, R. D., ARCHER, N., FRAY, R. G., RAKHA, E., JEYAPALAN, J. N., RUTLAND, C. S., MONGAN, N. P. and WOODCOCK, C. L., 2022. Clinical and molecular significance of the RNA m(6)A methyltransferase complex in prostate cancer: Front Genet Front Genet. 13, 1096071
• KULKARNI, S., BROWNLIE, J., JEYAPALAN, J. N., MONGAN, N. P., RAKHA, E. A. and MADHUSUDAN, S., 2022. Evolving DNA repair synthetic lethality targets in cancer: Biosci Rep Biosci Rep. 42(12),
• HARRIS, A. E., METZLER, V. M., LOTHION-ROY, J., VARUN, D., WOODCOCK, C. L., HAIGH, D. B., ENDELEY, C., HAQUE, M., TOSS, M. S., ALSALEEM, M., PERSSON, J. L., GUDAS, L. J., RAKHA, E., ROBINSON, B. D., KHANI, F., MARTIN, L. M., MOYER, J. E., BROWNLIE, J., MADHUSUDAN, S., ALLEGRUCCI, C., JAMES, V. H., RUTLAND, C. S., FRAY, R. G., NTEKIM, A., DE BROT, S., MONGAN, N. P. and JEYAPALAN, J. N., 2022. Exploring anti-androgen therapies in hormone dependent prostate cancer and new therapeutic routes for castration resistant prostate cancer: Front Endocrinol (Lausanne) Front Endocrinol (Lausanne). 13, 1006101
• HAIGH, D. B., WOODCOCK, C. L., LOTHION-ROY, J., HARRIS, A. E., METZLER, V. M., PERSSON, J. L., ROBINSON, B. D., KHANI, F., ALSALEEM, M., NTEKIM, A., MADHUSUDAN, S., DAVIS, M. B., LAURSEN, K. B., GUDAS, L. J., RUTLAND, C. S., TOSS, M. S., ARCHER, N., BODI, Z., RAKHA, E. A., FRAY, R. G., JEYAPALAN, J. N. and MONGAN, N. P., 2022. The METTL3 RNA Methyltransferase Regulates Transcriptional Networks in Prostate Cancer: Cancers (Basel) Cancers (Basel). 14(20),
• BAHL, A., WILSON, W., BALL, J., RENNINSON, E., DUBEY, S., BRAVO, A., FOULSTONE, E., SPENSLEY, S., BOWEN, R., MANSI, J., WATERS, S., RIDDLE, P., WHEATLEY, D., STEPHENS, P., BEZECNY, P., MADHUSUDAN, S., VERRILL, M., BRAYBROOKE, J., COMINS, C., MOHAN, V., GEE, A., KIRK, H., MARKHAM, A., EVANS, H., WATSON, E., CALLAWAY, M., PEARSON, S., HACKSHAW, A. and CHURN, M., 2022. Concept: A randomised multicentre trial of first line chemotherapy comparing three weekly cabazitaxel versus weekly paclitaxel in HER2 negative metastatic breast cancer: Breast Breast. 66, 69-76
• ALI, R., AOUIDA, M., ALHAJ SULAIMAN, A., MADHUSUDAN, S. and RAMOTAR, D., 2022. Can Cisplatin Therapy Be Improved? Pathways That Can Be Targeted: Int J Mol Sci Int J Mol Sci. 23(13),
• ALGETHAMI, M., KULKARNI, S., SADIQ, M. T., TANG, H. K. C., BROWNLIE, J., JEYAPALAN, J. N., MONGAN, N. P., RAKHA, E. A. and MADHUSUDAN, S., 2022. Towards Personalized Management of Ovarian Cancer: Cancer Manag Res Cancer Manag Res. 14, 3469-3483
• ALBLIHY, A., ALI, R., ALGETHAMI, M., SHOQAFI, A., TOSS, M. S., BROWNLIE, J., TATUM, N. J., HICKSON, I., MORAN, P. O., GRABOWSKA, A., JEYAPALAN, J. N., MONGAN, N. P., RAKHA, E. A. and MADHUSUDAN, S., 2022. Targeting Mre11 overcomes platinum resistance and induces synthetic lethality in XRCC1 deficient epithelial ovarian cancers: NPJ Precis Oncol NPJ Precis Oncol. 6(1), 51
• SAVVA, C., SADIQ, M., SHEIKH, O., KARIM, S., TRIVEDI, S., GREEN, A. R., RAKHA, E. A., MADHUSUDAN, S. and ARORA, A., 2021. Werner Syndrome Protein Expression in Breast Cancer: Clin Breast Cancer Clin Breast Cancer. 21(1), 57-73 e7
• MESQUITA, K. A., ALI, R., DOHERTY, R., TOSS, M. S., MILIGY, I., ALBLIHY, A., DORJSUREN, D., SIMEONOV, A., JADHAV, A., WILSON, D. M., 3RD, HICKSON, I., TATUM, N. J., RAKHA, E. A. and MADHUSUDAN, S., 2021. FEN1 Blockade for Platinum Chemo-Sensitization and Synthetic Lethality in Epithelial Ovarian Cancers: Cancers (Basel) Cancers (Basel). 13(8),
• LU, X., REDON, C. E., TANG, W., PARVATHANENI, S., BOKHARI, B., DEBNATH, S., LI, X. L., MUYS, B. R., SONG, Y., PONGOR, L. S., SHEIKH, O., GREEN, A. R., MADHUSUDAN, S., LAL, A., AMBS, S., KHAN, J., ALADJEM, M. I. and SHARMA, S., 2021. Genome-Wide Analysis Unveils DNA Helicase RECQ1 as a Regulator of Estrogen Response Pathway in Breast Cancer Cells: Mol Cell Biol Mol Cell Biol. 41(4),
• AL-KAWAZ, A., MILIGY, I. M., TOSS, M. S., MOHAMMED, O. J., GREEN, A. R., MADHUSUDAN, S. and RAKHA, E. A., 2021. The prognostic significance of Flap Endonuclease 1 (FEN1) in breast ductal carcinoma in situ: Breast Cancer Res Treat Breast Cancer Res Treat. 188(1), 53-63
• AL-KAWAZ, A., ALI, R., TOSS, M. S., MILIGY, I. M., MOHAMMED, O. J., GREEN, A. R., MADHUSUDAN, S. and RAKHA, E. A., 2021. The frequency and clinical significance of DNA polymerase beta (POLbeta) expression in breast ductal carcinoma in situ (DCIS): Breast Cancer Res Treat Breast Cancer Res Treat. 190(1), 39-51
• ALI, R., ALBLIHY, A., MILIGY, I. M., ALABDULLAH, M. L., ALSALEEM, M., TOSS, M. S., ALGETHAMI, M., ABDEL-FATAH, T., MOSELEY, P., CHAN, S., MONGAN, N. P., NARAYAN, S., RAKHA, E. A. and MADHUSUDAN, S., 2021. Molecular disruption of DNA polymerase beta for platinum sensitisation and synthetic lethality in epithelial ovarian cancers: Oncogene Oncogene. 40(14), 2496-2508
• ALI, R., ALABDULLAH, M., ALGETHAMI, M., ALBLIHY, A., MILIGY, I., SHOQAFI, A., MESQUITA, K. A., ABDEL-FATAH, T., CHAN, S. Y., CHIANG, P. W., MONGAN, N. P., RAKHA, E. A., TOMKINSON, A. E. and MADHUSUDAN, S., 2021. Ligase 1 is a predictor of platinum resistance and its blockade is synthetically lethal in XRCC1 deficient epithelial ovarian cancers: Theranostics Theranostics. 11(17), 8350-8361
• ALBLIHY, A., SHOQAFI, A., TOSS, M. S., ALGETHAMI, M., HARRIS, A. E., JEYAPALAN, J. N., ABDEL-FATAH, T., SERVANTE, J., CHAN, S. Y. T., GREEN, A., MONGAN, N. P., RAKHA, E. A. and MADHUSUDAN, S., 2021. Untangling the clinicopathological significance of MRE11-RAD50-NBS1 complex in sporadic breast cancers: NPJ Breast Cancer NPJ Breast Cancer. 7(1), 143
• ALBLIHY, A., ALABDULLAH, M. L., ALI, R., ALGETHAMI, M., TOSS, M. S., MONGAN, N. P., RAKHA, E. A. and MADHUSUDAN, S., 2021. Clinicopathological and Functional Evaluation Reveal NBS1 as a Predictor of Platinum Resistance in Epithelial Ovarian Cancers: Biomedicines Biomedicines. 9(1),
• TIVADAR, S. T., MCINTOSH, R. S., CHUA, J. X., MOSS, R., PARSONS, T., ZAITOUN, A. M., MADHUSUDAN, S., DURRANT, L. G. and VANKEMMELBEKE, M., 2020. Monoclonal Antibody Targeting Sialyl-di-Lewis(a)-Containing Internalizing and Noninternalizing Glycoproteins with Cancer Immunotherapy Development Potential: Mol Cancer Ther Mol Cancer Ther. 19(3), 790-801
• ALI, R., ALBLIHY, A., TOSS, M. S., ALGETHAMI, M., AL SUNNI, R., GREEN, A. R., RAKHA, E. A. and MADHUSUDAN, S., 2020. XRCC1 deficient triple negative breast cancers are sensitive to ATR, ATM and Wee1 inhibitor either alone or in combination with olaparib: Ther Adv Med Oncol Ther Adv Med Oncol. 12, 1758835920974201
• ALI, R., ALABDULLAH, M., ALBLIHY, A., MILIGY, I., MESQUITA, K. A., CHAN, S. Y., MOSELEY, P., RAKHA, E. A. and MADHUSUDAN, S., 2020. PARP1 blockade is synthetically lethal in XRCC1 deficient sporadic epithelial ovarian cancers: Cancer Lett Cancer Lett. 469, 124-133
• ALBLIHY, A., ALABDULLAH, M. L., TOSS, M. S., ALGETHAMI, M., MONGAN, N. P., RAKHA, E. A. and MADHUSUDAN, S., 2020. RAD50 deficiency is a predictor of platinum sensitivity in sporadic epithelial ovarian cancers: Mol Biomed Mol Biomed. 1(1), 19
• SAVVA, C., ADHIKAREE, J., MADHUSUDAN, S. and CHOKKALINGAM, K., 2019. Oncogenic osteomalacia and metastatic breast cancer: a case report and review of the literature: J Diabetes Metab Disord J Diabetes Metab Disord. 18(1), 267-272
• MESQUITA, K. A., ALABDULLAH, M., GRIFFIN, M., TOSS, M. S., FATAH, TMAA, ALBLIHY, A., MOSELEY, P., CHAN, S. Y. T., RAKHA, E. A. and MADHUSUDAN, S., 2019. ERCC1-XPF deficiency is a predictor of olaparib induced synthetic lethality and platinum sensitivity in epithelial ovarian cancers: Gynecol Oncol Gynecol Oncol. 153(2), 416-424
• KAYE, P., LINDSAY, D., MADHUSUDAN, S., VOHRA, R., CATTON, J., PLATT, C. and RAGUNATH, K., 2019. Upper GI biopsies for adenocarcinoma - how many biopsies should endoscopists take?: Histopathology Histopathology. 74(6), 959-963
• ALI, R., ALABDULLAH, M., MILIGY, I., NORMATOVA, M., BABAEI-JADIDI, R., NATERI, A. S., RAKHA, E. A. and MADHUSUDAN, S., 2019. ATM Regulated PTEN Degradation Is XIAP E3 Ubiquitin Ligase Mediated in p85alpha Deficient Cancer Cells and Influence Platinum Sensitivity: Cells Cells. 8(10),
• ALABDULLAH, M. L., AHMAD, D. A., MOSELEY, P., MADHUSUDAN, S., CHAN, S. and RAKHA, E., 2019. The mTOR downstream regulator (p-4EBP1) is a novel independent prognostic marker in ovarian cancer: J Obstet Gynaecol J Obstet Gynaecol. 39(4), 522-528
• ABDEL-FATAH, T. M. A., ALI, R., SADIQ, M., MOSELEY, P. M., MESQUITA, K. A., BALL, G., GREEN, A. R., RAKHA, E. A., CHAN, S. Y. T. and MADHUSUDAN, S., 2019. ERCC1 Is a Predictor of Anthracycline Resistance and Taxane Sensitivity in Early Stage or Locally Advanced Breast Cancers: Cancers (Basel) Cancers (Basel). 11(8),
• SAVVA, C., KAYE, P., SOOMRO, I., PARSONS, S. L., JAMES, E. and MADHUSUDAN, S., 2018. Primary Esophagogastric Neuroendocrine Carcinoma: a Retrospective Study from the Nottingham Upper Gastrointestinal Cancer Center: J Gastrointest Cancer J Gastrointest Cancer. 49(1), 85-92
• NG, O., KEELER, B., SIMPSON, J. A., MADHUSUDAN, S., BROOKES, M. and ACHESON, A., 2018. Feasibility of Intravenous Iron Isomaltoside to Improve Anemia and Quality of Life During Palliative Chemotherapy for Esophagogastric Adenocarcinoma: Nutr Cancer Nutr Cancer. 70(7), 1106-1117
• NAIDOO, K., WAI, P. T., MAGUIRE, S. L., DALEY, F., HAIDER, S., KRIPLANI, D., CAMPBELL, J., MIRZA, H., GRIGORIADIS, A., TUTT, A., MOSELEY, P. M., ABDEL-FATAH, T. M. A., CHAN, S. Y. T., MADHUSUDAN, S., RHAKA, E. A., ELLIS, I. O., LORD, C. J., YUAN, Y., GREEN, A. R. and NATRAJAN, R., 2018. Evaluation of CDK12 Protein Expression as a Potential Novel Biomarker for DNA Damage Response-Targeted Therapies in Breast Cancer: Mol Cancer Ther Mol Cancer Ther. 17(1), 306-315
• GOLAN, T., GEVA, R., RICHARDS, D., MADHUSUDAN, S., LIN, B. K., WANG, H. T., WALGREN, R. A. and STEMMER, S. M., 2018. LY2495655, an antimyostatin antibody, in pancreatic cancer: a randomized, phase 2 trial: J Cachexia Sarcopenia Muscle J Cachexia Sarcopenia Muscle. 9(5), 871-879
• BARONE, G., ARORA, A., GANESH, A., ABDEL-FATAH, T., MOSELEY, P., ALI, R., CHAN, S. Y., SAVVA, C., SCHIAVONE, K., CARMELL, N., MYERS, K. N., RAKHA, E. A., MADHUSUDAN, S. and COLLIS, S. J., 2018. The relationship of CDK18 expression in breast cancer to clinicopathological parameters and therapeutic response: Oncotarget Oncotarget. 9(50), 29508-29524
• BACKEN, A. C., LOPES, A., WASAN, H., PALMER, D. H., DUGGAN, M., CUNNINGHAM, D., ANTHONEY, A., CORRIE, P. G., MADHUSUDAN, S., MARAVEYAS, A., ROSS, P. J., WATERS, J. S., STEWARD, W. P., REES, C., MCNAMARA, M. G., BEARE, S., BRIDGEWATER, J. A., DIVE, C. and VALLE, J. W., 2018. Circulating biomarkers during treatment in patients with advanced biliary tract cancer receiving cediranib in the UK ABC-03 trial: Br J Cancer Br J Cancer. 119(1), 27-35
• AL-SUBHI, N., ALI, R., ABDEL-FATAH, T., MOSELEY, P. M., CHAN, S. Y. T., GREEN, A. R., ELLIS, I. O., RAKHA, E. A. and MADHUSUDAN, S., 2018. Targeting ataxia telangiectasia-mutated- and Rad3-related kinase (ATR) in PTEN-deficient breast cancers for personalized therapy: Breast Cancer Res Treat Breast Cancer Res Treat. 169(2), 277-286
• ALI, R., AL-KAWAZ, A., TOSS, M. S., GREEN, A. R., MILIGY, I. M., MESQUITA, K. A., SEEDHOUSE, C., MIRZA, S., BAND, V., RAKHA, E. A. and MADHUSUDAN, S., 2018. Targeting PARP1 in XRCC1-Deficient Sporadic Invasive Breast Cancer or Preinvasive Ductal Carcinoma In Situ Induces Synthetic Lethality and Chemoprevention: Cancer Res Cancer Res. 78(24), 6818-6827
• MIDDLETON G., PALMER DH, GREENHALF W, GHANEH P, JACKSON R, COX T, EVANS A, WADSLEY J, VALLE J, PROPPER D, WASAN H, FALK S, CUNNINGHAM D, COXON F, ROSS P, MADHUSUDAN S, WADD N, CORRIE P, HICKISH T, COSTELLO E, CAMPBELL F, RAWCLIFFE C, AND NEOPTOLEMOS J., 2017. A prospective, phase II, double blind multicentre randomised controlled trial comparing gemcitabine plus vandetanib with gemcitabine plus placebo in locally advanced or metastatic pancreatic cancer Lancet Oncology. 18(4), 486-499
• SAVVA C, KAYE P, SOOMRO I, PARSONS SL, JAMES E and MADHUSUDAN S, 2017. Primary Esophagogastric Neuroendocrine Carcinoma: a Retrospective Study from the Nottingham Upper Gastrointestinal Cancer Center. Journal of gastrointestinal cancer. (In Press.)
• PARVATHANENI S, LU X, CHAUDHARY R, LAL A, MADHUSUDAN S and SHARMA S, 2017. RECQ1 expression is upregulated in response to DNA damage and in a p53-dependent manner. Oncotarget. 8(44), 75924-75942
• REECE-SMITH AM, SAUNDERS JH, SOOMRO IN, BOWMAN CR, DUFFY JP, KAYE PV, WELCH NT, MADHUSUDAN S and PARSONS SL, 2017. Postoperative survival following perioperative MAGIC versus neoadjuvant OE02-type chemotherapy in oesophageal adenocarcinoma. Annals of the Royal College of Surgeons of England. 99(5), 378-384
• GREEN, A. R., ALESKANDARANY, M. A., ALI, R., HODGSON, E. G., ATABANI, S., DE SOUZA, K., RAKHA, E. A., ELLIS, I. O. and MADHUSUDAN, S., 2017. Clinical Impact of Tumor DNA Repair Expression and T-cell Infiltration in Breast Cancers Cancer Immunol Res. 5(4), 292-299
• ARORA, A., PARVATHANENI, S., ALESKANDARANY, M. A., AGARWAL, D., ALI, R., ABDEL-FATAH, T., GREEN, A. R., BALL, G. R., RAKHA, E. A., ELLIS, I. O., SHARMA, S. and MADHUSUDAN, S., 2017. Clinicopathological and Functional Significance of RECQL1 Helicase in Sporadic Breast Cancers Mol Cancer Ther. 16(1), 239-250
• SAUNDERS, J. H., BOWMAN, C. R., REECE-SMITH, A. M., PANG, V., DORRINGTON, M. S., MUMTAZ, E., SOOMRO, I., KAYE, P., MADHUSUDAN, S. and PARSONS, S. L., 2017. The role of adjuvant platinum-based chemotherapy in esophagogastric cancer patients who received neoadjuvant chemotherapy prior to definitive surgery: J Surg Oncol J Surg Oncol. 115(7), 821-829
• REECE-SMITH, A. M., SAUNDERS, J. H., SOOMRO, I. N., BOWMAN, C. R., DUFFY, J. P., KAYE, P. V., WELCH, N. T., MADHUSUDAN, S. and PARSONS, S. L., 2017. Postoperative survival following perioperative MAGIC versus neoadjuvant OE02-type chemotherapy in oesophageal adenocarcinoma: Ann R Coll Surg Engl Ann R Coll Surg Engl. 99(5), 378-384
• PARVATHANENI, S., LU, X., CHAUDHARY, R., LAL, A., MADHUSUDAN, S. and SHARMA, S., 2017. RECQ1 expression is upregulated in response to DNA damage and in a p53-dependent manner: Oncotarget Oncotarget. 8(44), 75924-75942
• MIDDLETON, G., PALMER, D. H., GREENHALF, W., GHANEH, P., JACKSON, R., COX, T., EVANS, A., SHAW, V. E., WADSLEY, J., VALLE, J. W., PROPPER, D., WASAN, H., FALK, S., CUNNINGHAM, D., COXON, F., ROSS, P., MADHUSUDAN, S., WADD, N., CORRIE, P., HICKISH, T., COSTELLO, E., CAMPBELL, F., RAWCLIFFE, C. and NEOPTOLEMOS, J. P., 2017. Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial: Lancet Oncol Lancet Oncol. 18(4), 486-499
• GREEN, A. R., ALESKANDARANY, M. A., ALI, R., HODGSON, E. G., ATABANI, S., DE SOUZA, K., RAKHA, E. A., ELLIS, I. O. and MADHUSUDAN, S., 2017. Clinical Impact of Tumor DNA Repair Expression and T-cell Infiltration in Breast Cancers: Cancer Immunol Res Cancer Immunol Res. 5(4), 292-299
• ARORA, A., PARVATHANENI, S., ALESKANDARANY, M. A., AGARWAL, D., ALI, R., ABDEL-FATAH, T., GREEN, A. R., BALL, G. R., RAKHA, E. A., ELLIS, I. O., SHARMA, S. and MADHUSUDAN, S., 2017. Clinicopathological and Functional Significance of RECQL1 Helicase in Sporadic Breast Cancers: Mol Cancer Ther Mol Cancer Ther. 16(1), 239-250
• ALI, R., RAKHA, E. A., MADHUSUDAN, S. and BRYANT, H. E., 2017. DNA damage repair in breast cancer and its therapeutic implications: Pathology Pathology. 49(2), 156-165
• ALSUBHI N, MIDDLETON F, ABDEL-FATAH TMA, STEPHENS P, DOHERTY R, ARORA A, MOSELEY PM, CHAN SYT, ALESKANDARANY MA, GREEN AR, RAKHA EA, ELLIS IO, MARTIN SG, CURTIN NJ and MADHUSUDAN S, 2016. Chk1 phosphorylated at serine345 is a predictor of early local recurrence and radio-resistance in breast cancer Molecular Oncology. 10(2), 213-223
• ARORA, A., ABDEL-FATAH, T. M., AGARWAL, D., DOHERTY, R., CROTEAU, D. L., MOSELEY, P. M., HAMEED, K., GREEN, A., ALESKANDARANY, M. A., RAKHA, E. A., PATTERSON, K., BALL, G., CHAN, S. Y., ELLIS, I. O., BOHR, V. A., BRYANT, H. E. and MADHUSUDAN, S., 2016. Clinicopathological and prognostic significance of RECQL5 helicase expression in breast cancers: Carcinogenesis Carcinogenesis. 37(1), 63-71
• ARORA, A., AGARWAL, D., ABDEL-FATAH, T.M.A., LU, H., CROTEAU, D.L., MOSELEY, P., ALESKANDARANY, M.A., GREEN, A.R., BALL, G., RAKHA, E.A., CHAN, S.Y.T., ELLIS, I.O., WANG, L.L., ZHAO, Y., BALAJEE, A.S., BOHR, V.A. and MADHUSUDAN, S., 2016. RECQL4 helicase has oncogenic potential in sporadic breast cancers Journal of Pathology. 238(4), 495-501
• MO D, FANG H, NIU K, LIU J, WU M, LI S, ZHU T, ALESKANDARANY MA, ARORA A, LOBO DN, MADHUSUDAN S, BALAJEE AS, CHI Z, ZHAO Y, 2016. Human Helicase RECQL4 Drives Cisplatin Resistance in Gastric Cancer by Activating an AKT-YB1-MDR1 Signaling Pathway. Cancer Research. 15(76), 10
• ALSHAREEDA AT, NEGM OH, ALESKANDARANY MA, GREEN AR, NOLAN C, TIGHHE PJ, MADHUSUDAN S, ELLIS IO and RAKHA EA, 2016. Clinical and biological significance of RAD51 expression in breast cancer: a key DNA damage response protein. Breast cancer research and treatment. 159(1), 41-53
• BRIDGEWATER J, LOPES A, PALMER D, CUNNINGHAM D, ANTHONEY A, MARAVEYAS A, MADHUSUDAN S, IVESON T, VALLE J and WASAN H, 2016. Quality of life, long-term survivors and long-term outcome from the ABC-02 study. British journal of cancer. 114(9), 965-71
• MO D, FANG H, NIU K, LIU J, WU M, LI S, ZHU T, ALESKANDARANY MA, ARORA A, LOBO DN, MADHUSUDAN S, BALAJEE AS, CHI Z and ZHAO Y, 2016. Human Helicase RECQL4 Drives Cisplatin Resistance in Gastric Cancer by Activating an AKT-YB1-MDR1 Signaling Pathway. Cancer research. 76(10), 3057-66
• ROLLINS, K.E., TEWARI, N., ACKNER, A., AWWAD, A., MADHUSUDAN, S., MACDONALD, I.A., FEARON, K.C.H. and LOBO, D.N., 2016. The impact of sarcopenia and myosteatosis on outcomes of unresectable pancreatic cancer or distal cholangiocarcinoma Clinical Nutrition. 35(5), 1103-1109
• ALI R, RAKHA EA, MADHUSUDAN S and BRYANT HE, 2016. DNA damage repair in breast cancer and its therapeutic implications. Pathology. 49(2), 156-165
• SHAMANNA, R. A., LU, H., CROTEAU, D. L., ARORA, A., AGARWAL, D., BALL, G., ALESKANDARANY, M. A., ELLIS, I. O., POMMIER, Y., MADHUSUDAN, S. and BOHR, V. A., 2016. Camptothecin targets WRN protein: mechanism and relevance in clinical breast cancer Oncotarget. 7(12), 13269-84
• ROLLINS, K. E., TEWARI, N., ACKNER, A., AWWAD, A., MADHUSUDAN, S., MACDONALD, I. A., FEARON, K. C. and LOBO, D. N., 2016. The impact of sarcopenia and myosteatosis on outcomes of unresectable pancreatic cancer or distal cholangiocarcinoma: Clin Nutr Clin Nutr. 35(5), 1103-9
• GREEN, A. R., ALESKANDARANY, M. A., AGARWAL, D., ELSHEIKH, S., NOLAN, C. C., DIEZ-RODRIGUEZ, M., MACMILLAN, R. D., BALL, G. R., CALDAS, C., MADHUSUDAN, S., ELLIS, I. O. and RAKHA, E. A., 2016. MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours: Br J Cancer Br J Cancer. 114(8), 917-28
• MO, D., FANG, H., NIU, K., LIU, J., WU, M., LI, S., ZHU, T., ALESKANDARANY, M. A., ARORA, A., LOBO, D. N., MADHUSUDAN, S., BALAJEE, A. S., CHI, Z. and ZHAO, Y., 2016. Human Helicase RECQL4 Drives Cisplatin Resistance in Gastric Cancer by Activating an AKT-YB1-MDR1 Signaling Pathway: Cancer Res Cancer Res. 76(10), 3057-66
• BRIDGEWATER, J., LOPES, A., PALMER, D., CUNNINGHAM, D., ANTHONEY, A., MARAVEYAS, A., MADHUSUDAN, S., IVESON, T., VALLE, J. and WASAN, H., 2016. Quality of life, long-term survivors and long-term outcome from the ABC-02 study: Br J Cancer Br J Cancer. 114(9), 965-71
• ARORA, A., AGARWAL, D., ABDEL-FATAH, T. M., LU, H., CROTEAU, D. L., MOSELEY, P., ALESKANDARANY, M. A., GREEN, A. R., BALL, G., RAKHA, E. A., CHAN, S. Y., ELLIS, I. O., WANG, L. L., ZHAO, Y., BALAJEE, A. S., BOHR, V. A. and MADHUSUDAN, S., 2016. RECQL4 helicase has oncogenic potential in sporadic breast cancers: J Pathol J Pathol. 238(4), 495-501
• ARORA, A., ABDEL-FATAH, T. M., AGARWAL, D., DOHERTY, R., CROTEAU, D. L., MOSELEY, P. M., HAMEED, K., GREEN, A., ALESKANDARANY, M. A., RAKHA, E. A., PATTERSON, K., BALL, G., CHAN, S. Y., ELLIS, I. O., BOHR, V. A., BRYANT, H. E. and MADHUSUDAN, S., 2016. Clinicopathological and prognostic significance of RECQL5 helicase expression in breast cancers: Carcinogenesis Carcinogenesis. 37(1), 63-71
• ALSUBHI, N., MIDDLETON, F., ABDEL-FATAH, T. M., STEPHENS, P., DOHERTY, R., ARORA, A., MOSELEY, P. M., CHAN, S. Y., ALESKANDARANY, M. A., GREEN, A. R., RAKHA, E. A., ELLIS, I. O., MARTIN, S. G., CURTIN, N. J. and MADHUSUDAN, S., 2016. Chk1 phosphorylated at serine345 is a predictor of early local recurrence and radio-resistance in breast cancer: Mol Oncol Mol Oncol. 10(2), 213-23
• ALSHAREEDA, A. T., NEGM, O. H., ALESKANDARANY, M. A., GREEN, A. R., NOLAN, C., TIGHHE, P. J., MADHUSUDAN, S., ELLIS, I. O. and RAKHA, E. A., 2016. Clinical and biological significance of RAD51 expression in breast cancer: a key DNA damage response protein: Breast Cancer Res Treat Breast Cancer Res Treat. 159(1), 41-53
• ALBARAKATI, NADA, ABDEL-FATAH, TAREK M. A., DOHERTY, RACHEL, RUSSELL, ROSLIN, AGARWAL, DEVIKA, MOSELEY, PAUL, PERRY, CHRISTINA, ARORA, ARVIND, ALSUBHI, NOUF, SEEDHOUSE, CLAIRE, RAKHA, EMAD A., GREEN, ANDREW, BALL, GRAHAM, CHAN, STEPHEN, CALDAS, CARLOS, ELLIS, IAN O. and MADHUSUDAN, SRINIVASAN, 2015. Targeting BRCA1-BER deficient breast cancer by ATM or DNA-PKcs blockade either alone or in combination with cisplatin for personalized therapy MOLECULAR ONCOLOGY. 9(1), 204-217
• ABDEL-FATAH TM, ARORA A, MOSELEY PM, PERRY C, RAKHA EA, GREEN AR, CHAN SY, ELLIS IO, MADHUSUDAN S., 2015. DNA repair prognostic index modelling reveals an essential role for base excision repair in influencing clinical outcomes in ER negative and triple negative breast cancers. Oncotarget. 6(26), 21964-78.
• VALLE JW, WASAN H, LOPES A, BACKEN AC, PALMER DH, MORRIS K, DUGGAN M, CUNNINGHAM D, ANTHONEY DA, CORRIE P, MADHUSUDAN S, MARAVEYAS A, ROSS PJ, WATERS JS, STEWARD WP, REES C, BEARE S, DIVE C, BRIDGEWATER JA., 2015. Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial. Lancet Oncology. 2015 Aug;. 16(8), 967-78.
• ROBERTSON, E., PERRY, C., DOHERTY, R. and MADHUSUDAN, S., 2015. Transcriptomic profiling of Forkhead box transcription factors in adult glioblastoma multiforme: Cancer Genomics Proteomics Cancer Genomics Proteomics. 12(3), 103-12
• PERRY, C., SOOMRO, I., KAYE, P., HARDY, E., PARSONS, S. L., RAGUNATH, K., LOBO, D. N., MARTIN, S. G. and MADHUSUDAN, S., 2015. Analysis of lymphatic and blood vessel invasion biomarkers in T1 esophagogastric adenocarcinomas for improved patient prognostication: Dis Esophagus Dis Esophagus. 28(3), 262-8
• GREEN, A. R., CARACAPPA, D., BENHASOUNA, A. A., ALSHAREEDA, A., NOLAN, C. C., MACMILLAN, R. D., MADHUSUDAN, S., ELLIS, I. O. and RAKHA, E. A., 2015. Biological and clinical significance of PARP1 protein expression in breast cancer: Breast Cancer Res Treat Breast Cancer Res Treat. 149(2), 353-62
• ELEFTHERIOU, M., PASCUAL, A. J., WHELDON, L. M., PERRY, C., ABAKIR, A., ARORA, A., JOHNSON, A. D., AUER, D. T., ELLIS, I. O., MADHUSUDAN, S. and RUZOV, A., 2015. 5-Carboxylcytosine levels are elevated in human breast cancers and gliomas: Clin Epigenetics Clin Epigenetics. 7(1), 88
• DOHERTY, R. and MADHUSUDAN, S., 2015. DNA Repair Endonucleases: Physiological Roles and Potential as Drug Targets: J Biomol Screen J Biomol Screen. 20(7), 829-41
• CHUA, J. X., VANKEMMELBEKE, M., MCINTOSH, R. S., CLARKE, P. A., MOSS, R., PARSONS, T., SPENDLOVE, I., ZAITOUN, A. M., MADHUSUDAN, S. and DURRANT, L. G., 2015. Monoclonal Antibodies Targeting LecLex-Related Glycans with Potent Antitumor Activity: Clin Cancer Res Clin Cancer Res. 21(13), 2963-74
• ARORA, A., ABDEL-FATAH, T. M., AGARWAL, D., DOHERTY, R., MOSELEY, P. M., ALESKANDARANY, M. A., GREEN, A. R., BALL, G., ALSHAREEDA, A. T., RAKHA, E. A., CHAN, S. Y., ELLIS, I. O. and MADHUSUDAN, S., 2015. Transcriptomic and Protein Expression Analysis Reveals Clinicopathological Significance of Bloom Syndrome Helicase (BLM) in Breast Cancer: Mol Cancer Ther Mol Cancer Ther. 14(4), 1057-65
• ALSHAREEDA, A. T., NEGM, O. H., GREEN, A. R., NOLAN, C. C., TIGHE, P., ALBARAKATI, N., SULTANA, R., MADHUSUDAN, S., ELLIS, I. O. and RAKHA, E. A., 2015. KPNA2 is a nuclear export protein that contributes to aberrant localisation of key proteins and poor prognosis of breast cancer: Br J Cancer Br J Cancer. 112(12), 1929-37
• AL-KAABI, M. M., ALSHAREEDA, A. T., JERJEES, D. A., MUFTAH, A. A., GREEN, A. R., ALSUBHI, N. H., NOLAN, C. C., CHAN, S., CORNFORD, E., MADHUSUDAN, S., ELLIS, I. O. and RAKHA, E. A., 2015. Checkpoint kinase1 (CHK1) is an important biomarker in breast cancer having a role in chemotherapy response: Br J Cancer Br J Cancer. 112(5), 901-11
• ALBARAKATI, N., ABDEL-FATAH, T. M., DOHERTY, R., RUSSELL, R., AGARWAL, D., MOSELEY, P., PERRY, C., ARORA, A., ALSUBHI, N., SEEDHOUSE, C., RAKHA, E. A., GREEN, A., BALL, G., CHAN, S., CALDAS, C., ELLIS, I. O. and MADHUSUDAN, S., 2015. Targeting BRCA1-BER deficient breast cancer by ATM or DNA-PKcs blockade either alone or in combination with cisplatin for personalized therapy: Mol Oncol Mol Oncol. 9(1), 204-17
• ABDEL-FATAH, T. M., MIDDLETON, F. K., ARORA, A., AGARWAL, D., CHEN, T., MOSELEY, P. M., PERRY, C., DOHERTY, R., CHAN, S., GREEN, A. R., RAKHA, E., BALL, G., ELLIS, I. O., CURTIN, N. J. and MADHUSUDAN, S., 2015. Untangling the ATR-CHEK1 network for prognostication, prediction and therapeutic target validation in breast cancer: Mol Oncol Mol Oncol. 9(3), 569-85
• ABDEL-FATAH, T. M., ARORA, A., MOSELEY, P. M., PERRY, C., RAKHA, E. A., GREEN, A. R., CHAN, S. Y., ELLIS, I. O. and MADHUSUDAN, S., 2015. DNA repair prognostic index modelling reveals an essential role for base excision repair in influencing clinical outcomes in ER negative and triple negative breast cancers: Oncotarget Oncotarget. 6(26), 21964-78
• ABDEL-FATAH TMA, RUSSELL R, MALONEY DJ, MOHAN M , DORJSUREN D, RUEDA OM, MOSELEY P, MUKHERJEE A , JADHAV A, SIMEONOV A, WILSON DM III , BALL G, CHAN S, CALDAS C, ELLIS IO, AND MADHUSUDAN S., 2014. Genomic and protein expression analysis reveals Flap endonuclease 1 (FEN1) as a key biomarker in breast and ovarian cancer . Molecular Oncology 8(7), 1326-38.
• ALBARAKATI N, ABDEL-FATAH TMA, DOHERTY R, RUSSELL R, AGARWAL D, MOSELEY P, PERRY C, ARORA A, ALSUBHI N, SEEDHOUSE C, RAKHA EA, GREEN A, BALL G, CHAN S, CALDAS C, ELLIS IO and MADHUSUDAN S, 2014. Targeting BRCA1-BER deficient breast cancer by ATM or DNA-PKcs blockade either alone or in combination with cisplatin for personalized therapy. Molecular oncology. 9(1), 204-17
• ABDEL-FATAH T, ARORA A, AGARWAL D, MOSELEY P, PERRY C, THOMPSON N, GREEN AR, RAKHA E, CHAN S, BALL G, ELLIS IO and MADHUSUDAN S, 2014. Adverse prognostic and predictive significance of low DNA-dependent protein kinase catalytic subunit (DNA-PKcs) expression in early-stage breast cancers. Breast cancer research and treatment. 146(2), 309-20
• SUDHAKAR, J., KHETAN, V., MADHUSUDAN, S. and KRISHNAKUMAR, S., 2014. Dysregulation of human apurinic/apyrimidinic endonuclease 1 (APE1) expression in advanced retinoblastoma: Br J Ophthalmol Br J Ophthalmol. 98(3), 402-7
• PERRY, C., AGARWAL, D., ABDEL-FATAH, T. M., LOURDUSAMY, A., GRUNDY, R., AUER, D. T., WALKER, D., LAKHANI, R., SCOTT, I. S., CHAN, S., BALL, G. and MADHUSUDAN, S., 2014. Dissecting DNA repair in adult high grade gliomas for patient stratification in the post-genomic era: Oncotarget Oncotarget. 5(14), 5764-81
• MIDDLETON, G., SILCOCKS, P., COX, T., VALLE, J., WADSLEY, J., PROPPER, D., COXON, F., ROSS, P., MADHUSUDAN, S., ROQUES, T., CUNNINGHAM, D., FALK, S., WADD, N., HARRISON, M., CORRIE, P., IVESON, T., ROBINSON, A., MCADAM, K., EATOCK, M., EVANS, J., ARCHER, C., HICKISH, T., GARCIA-ALONSO, A., NICOLSON, M., STEWARD, W., ANTHONEY, A., GREENHALF, W., SHAW, V., COSTELLO, E., NAISBITT, D., RAWCLIFFE, C., NANSON, G. and NEOPTOLEMOS, J., 2014. Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial: Lancet Oncol Lancet Oncol. 15(8), 829-40
• KHANNA, A., REECE-SMITH, A. M., CUNNELL, M., MADHUSUDAN, S., THOMAS, A., BOWREY, D. J. and PARSONS, S. L., 2014. Venous thromboembolism in patients receiving perioperative chemotherapy for esophagogastric cancer: Dis Esophagus Dis Esophagus. 27(3), 242-7
• FORD, H. E., MARSHALL, A., BRIDGEWATER, J. A., JANOWITZ, T., COXON, F. Y., WADSLEY, J., MANSOOR, W., FYFE, D., MADHUSUDAN, S., MIDDLETON, G. W., SWINSON, D., FALK, S., CHAU, I., CUNNINGHAM, D., KARECLAS, P., COOK, N., BLAZEBY, J. M., DUNN, J. A. and COUGAR- INVESTIGATORS, 2014. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial: Lancet Oncol Lancet Oncol. 15(1), 78-86
• ALSHAREEDA, A. T., NEGM, O. H., GREEN, A. R., NOLAN, C., TIGHE, P., ALBARAKATI, N., SULTANA, R., MADHUSUDAN, S., ELLIS, I. O. and RAKHA, E. A., 2014. SUMOylation proteins in breast cancer: Breast Cancer Res Treat Breast Cancer Res Treat. 144(3), 519-30
• ADHIKAREE, J. and MADHUSUDAN, S., 2014. Is there a role for second-line platinum re-challenge in advanced biliary tract cancers?: Med Oncol Med Oncol. 31(7), 46
• ABDEL-FATAH, T. M., RUSSELL, R., ALBARAKATI, N., MALONEY, D. J., DORJSUREN, D., RUEDA, O. M., MOSELEY, P., MOHAN, V., SUN, H., ABBOTTS, R., MUKHERJEE, A., AGARWAL, D., ILLUZZI, J. L., JADHAV, A., SIMEONOV, A., BALL, G., CHAN, S., CALDAS, C., ELLIS, I. O., WILSON, D. M., 3RD and MADHUSUDAN, S., 2014. Genomic and protein expression analysis reveals flap endonuclease 1 (FEN1) as a key biomarker in breast and ovarian cancer: Mol Oncol Mol Oncol. 8(7), 1326-38
• ABDEL-FATAH, T. M., RUSSELL, R., AGARWAL, D., MOSELEY, P., ABAYOMI, M. A., PERRY, C., ALBARAKATI, N., BALL, G., CHAN, S., CALDAS, C., ELLIS, I. O. and MADHUSUDAN, S., 2014. DNA polymerase beta deficiency is linked to aggressive breast cancer: a comprehensive analysis of gene copy number, mRNA and protein expression in multiple cohorts: Mol Oncol Mol Oncol. 8(3), 520-32
• ABDEL-FATAH, T. M., PERRY, C., MOSELEY, P., JOHNSON, K., ARORA, A., CHAN, S., ELLIS, I. O. and MADHUSUDAN, S., 2014. Clinicopathological significance of human apurinic/apyrimidinic endonuclease 1 (APE1) expression in oestrogen-receptor-positive breast cancer: Breast Cancer Res Treat Breast Cancer Res Treat. 143(3), 411-21
• ABDEL-FATAH, T. M., PERRY, C., ARORA, A., THOMPSON, N., DOHERTY, R., MOSELEY, P. M., GREEN, A. R., CHAN, S. Y., ELLIS, I. O. and MADHUSUDAN, S., 2014. Is there a role for base excision repair in estrogen/estrogen receptor-driven breast cancers?: Antioxid Redox Signal Antioxid Redox Signal. 21(16), 2262-8
• ABDEL-FATAH, T. M., ARORA, A., MOSELEY, P., COVENEY, C., PERRY, C., JOHNSON, K., KENT, C., BALL, G., CHAN, S. and MADHUSUDAN, S., 2014. ATM, ATR and DNA-PKcs expressions correlate to adverse clinical outcomes in epithelial ovarian cancers: BBA Clin BBA Clin. 2, 10-7
• ABDEL-FATAH, T. M., ARORA, A., ALSUBHI, N., AGARWAL, D., MOSELEY, P. M., PERRY, C., DOHERTY, R., CHAN, S. Y., GREEN, A. R., RAKHA, E., BALL, G., ELLIS, I. O. and MADHUSUDAN, S., 2014. Clinicopathological significance of ATM-Chk2 expression in sporadic breast cancers: a comprehensive analysis in large cohorts: Neoplasia Neoplasia. 16(11), 982-91
• ABDEL-FATAH, T., ARORA, A., AGARWAL, D., MOSELEY, P., PERRY, C., THOMPSON, N., GREEN, A. R., RAKHA, E., CHAN, S., BALL, G., ELLIS, I. O. and MADHUSUDAN, S., 2014. Adverse prognostic and predictive significance of low DNA-dependent protein kinase catalytic subunit (DNA-PKcs) expression in early-stage breast cancers: Breast Cancer Res Treat Breast Cancer Res Treat. 146(2), 309-20
• ABBOTTS, R., THOMPSON, N. and MADHUSUDAN, S., 2014. DNA repair in cancer: emerging targets for personalized therapy: Cancer Manag Res Cancer Manag Res. 6, 77-92
• ABBOTTS, R., JEWELL, R., NSENGIMANA, J., MALONEY, D. J., SIMEONOV, A., SEEDHOUSE, C., ELLIOTT, F., LAYE, J., WALKER, C., JADHAV, A., GRABOWSKA, A., BALL, G., PATEL, P. M., NEWTON-BISHOP, J., WILSON, D. M., 3RD and MADHUSUDAN, S., 2014. Targeting human apurinic/apyrimidinic endonuclease 1 (APE1) in phosphatase and tensin homolog (PTEN) deficient melanoma cells for personalized therapy: Oncotarget Oncotarget. 5(10), 3273-86
• TEWARI N, ZAITOUN AM, ARORA A, MADHUSUDAN S, ILYAS M and LOBO DN, 2013. The presence of tumour-associated lymphocytes confers a good prognosis in pancreatic ductal adenocarcinoma: an immunohistochemical study of tissue microarrays. BMC cancer. 13, 436
• WOOLSTON, C. M., MADHUSUDAN, S., SOOMRO, I. N., LOBO, D. N., REECE-SMITH, A. M., PARSONS, S. L. and MARTIN, S. G., 2013. Thioredoxin interacting protein and its association with clinical outcome in gastro-oesophageal adenocarcinoma: Redox Biol Redox Biol. 1(1), 285-91
• WANG, Q., FRANKS, H. A., LAX, S. J., EL REFAEE, M., MALECKA, A., SHAH, S., SPENDLOVE, I., GOUGH, M. J., SEEDHOUSE, C., MADHUSUDAN, S., PATEL, P. M. and JACKSON, A. M., 2013. The ataxia telangiectasia mutated kinase pathway regulates IL-23 expression by human dendritic cells: J Immunol J Immunol. 190(7), 3246-55
• TEWARI, N., ZAITOUN, A. M., ARORA, A., MADHUSUDAN, S., ILYAS, M. and LOBO, D. N., 2013. The presence of tumour-associated lymphocytes confers a good prognosis in pancreatic ductal adenocarcinoma: an immunohistochemical study of tissue microarrays: BMC Cancer BMC Cancer. 13, 436
• SULTANA, R., ABDEL-FATAH, T., PERRY, C., MOSELEY, P., ALBARAKTI, N., MOHAN, V., SEEDHOUSE, C., CHAN, S. and MADHUSUDAN, S., 2013. Ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase inhibition is synthetically lethal in XRCC1 deficient ovarian cancer cells: PLoS One PLoS One. 8(2), e57098
• SULTANA, R., ABDEL-FATAH, T., ABBOTTS, R., HAWKES, C., ALBARAKATI, N., SEEDHOUSE, C., BALL, G., CHAN, S., RAKHA, E. A., ELLIS, I. O. and MADHUSUDAN, S., 2013. Targeting XRCC1 deficiency in breast cancer for personalized therapy: Cancer Res Cancer Res. 73(5), 1621-34
• STORR, S. J., PU, X., DAVIS, J., LOBO, D., REECE-SMITH, A. M., PARSONS, S. L., MADHUSUDAN, S. and MARTIN, S. G., 2013. Expression of the calpain system is associated with poor clinical outcome in gastro-oesophageal adenocarcinomas: J Gastroenterol J Gastroenterol. 48(11), 1213-21
• OKINES, A. F., GONZALEZ DE CASTRO, D., CUNNINGHAM, D., CHAU, I., LANGLEY, R. E., THOMPSON, L. C., STENNING, S. P., SAFFERY, C., BARBACHANO, Y., COXON, F., MIDDLETON, G., FERRY, D., CROSBY, T., MADHUSUDAN, S., WADSLEY, J., WATERS, J., HALL, M., SWINSON, D., ROBINSON, A., SMITH, D., REIS-FILHO, J. S., WADDELL, T. S., PUCKEY, L., HULKKI WILSON, S., ELTAHIR, Z., BAND, M. and WOTHERSPOON, A., 2013. Biomarker analysis in oesophagogastric cancer: Results from the REAL3 and TransMAGIC trials: Eur J Cancer Eur J Cancer. 49(9), 2116-25
• ALSHAREEDA, A. T., NEGM, O. H., ALBARAKATI, N., GREEN, A. R., NOLAN, C., SULTANA, R., MADHUSUDAN, S., BENHASOUNA, A., TIGHE, P., ELLIS, I. O. and RAKHA, E. A., 2013. Clinicopathological significance of KU70/KU80, a key DNA damage repair protein in breast cancer: Breast Cancer Res Treat Breast Cancer Res Treat. 139(2), 301-10
• ABDEL-FATAH, T. M., PERRY, C., DICKINSON, P., BALL, G., MOSELEY, P., MADHUSUDAN, S., ELLIS, I. O. and CHAN, S. Y., 2013. Bcl2 is an independent prognostic marker of triple negative breast cancer (TNBC) and predicts response to anthracycline combination (ATC) chemotherapy (CT) in adjuvant and neoadjuvant settings: Ann Oncol Ann Oncol. 24(11), 2801-7
• ABDEL-FATAH, T. M., ALBARAKATI, N., BOWELL, L., AGARWAL, D., MOSELEY, P., HAWKES, C., BALL, G., CHAN, S., ELLIS, I. O. and MADHUSUDAN, S., 2013. Single-strand selective monofunctional uracil-DNA glycosylase (SMUG1) deficiency is linked to aggressive breast cancer and predicts response to adjuvant therapy: Breast Cancer Res Treat Breast Cancer Res Treat. 142(3), 515-27
• ABDEL-FATAH, T., SULTANA, R., ABBOTTS, R., HAWKES, C., SEEDHOUSE, C., CHAN, S. and MADHUSUDAN, S., 2013. Clinicopathological and functional significance of XRCC1 expression in ovarian cancer: Int J Cancer Int J Cancer. 132(12), 2778-86
• ABDEL-FATAH, T., ARORA, A., GORGUC, I., ABBOTTS, R., BEEBEEJAUN, S., STORR, S., MOHAN, V., HAWKES, C., SOOMRO, I., LOBO, D. N., PARSONS, S. L. and MADHUSUDAN, S., 2013. Are DNA repair factors promising biomarkers for personalized therapy in gastric cancer?: Antioxid Redox Signal Antioxid Redox Signal. 18(18), 2392-8
• SULTANA, R., MCNEILL, D. R., ABBOTTS, R., MOHAMMED, M. Z., ZDZIENICKA, M. Z., QUTOB, H., SEEDHOUSE, C., LAUGHTON, C. A., FISCHER, P. M., PATEL, P. M., WILSON, D. M., 3RD and MADHUSUDAN, S., 2012. Synthetic lethal targeting of DNA double-strand break repair deficient cells by human apurinic/apyrimidinic endonuclease inhibitors: Int J Cancer Int J Cancer. 131(10), 2433-44
• STORR, S. J., ZAITOUN, A. M., ARORA, A., DURRANT, L. G., LOBO, D. N., MADHUSUDAN, S. and MARTIN, S. G., 2012. Calpain system protein expression in carcinomas of the pancreas, bile duct and ampulla: BMC Cancer BMC Cancer. 12, 511
• REECE-SMITH, A. M., SAHA, S., CUNNELL, M. L., HAMEED, K., BESSELL, E. M., DUFFY, J. P., MADHUSUDAN, S. and PARSONS, S. L., 2012. MAGIC in practice: experience of peri-operative ECF/X chemotherapy in gastro-esophageal adenocarcinomas: J Surg Oncol J Surg Oncol. 106(6), 748-52
• MADHUSUDAN, S., 2012. Evolving drug targets in DNA base excision repair for cancer therapy: Curr Mol Pharmacol Curr Mol Pharmacol. 5(1), 1-2
• GOSSAGE, L., PERRY, C., ABBOTTS, R. and MADHUSUDAN, S., 2012. Base excision repair factors are promising prognostic and predictive markers in cancer: Curr Mol Pharmacol Curr Mol Pharmacol. 5(1), 115-24
• FAREED, K. R., SOOMRO, I. N., HAMEED, K., ARORA, A., LOBO, D. N., PARSONS, S. L. and MADHUSUDAN, S., 2012. Caspase-cleaved cytokeratin-18 and tumour regression in gastro-oesophageal adenocarcinomas treated with neoadjuvant chemotherapy: World J Gastroenterol World J Gastroenterol. 18(16), 1915-20
• ESQUEDA, A., MOHAMMED, M. Z., MADHUSUDAN, S. and NEAMATI, N., 2012. Purification and specific assays for measuring APE-1 endonuclease activity: Methods Mol Biol Methods Mol Biol. 928, 161-74
• DAVIES, J. R., RANDERSON-MOOR, J., KUKALIZCH, K., HARLAND, M., KUMAR, R., MADHUSUDAN, S., NAGORE, E., HANSSON, J., HOIOM, V., GHIORZO, P., GRUIS, N. A., KANETSKY, P. A., WENDT, J., PJANOVA, D., PUIG, S., SAIAG, P., SCHADENDORF, D., SOUFIR, N., OKAMOTO, I., AFFLECK, P., GARCIA-CASADO, Z., OGBAH, Z., OZOLA, A., QUEIROLO, P., SUCKER, A., BARRETT, J. H., VAN DOORN, R., BISHOP, D. T. and NEWTON-BISHOP, J., 2012. Inherited variants in the MC1R gene and survival from cutaneous melanoma: a BioGenoMEL study: Pigment Cell Melanoma Res Pigment Cell Melanoma Res. 25(3), 384-94
• ZHANG, J., STEVENS, M. F., HUMMERSONE, M., MADHUSUDAN, S., LAUGHTON, C. A. and BRADSHAW, T. D., 2011. Certain imidazotetrazines escape O6-methylguanine-DNA methyltransferase and mismatch repair: Oncology Oncology. 80(3-4), 195-207
• MUTHURAMALINGAM, S. R., BRAYBROOKE, J. P., BLANN, A. D., MADHUSUDAN, S., WILNER, S., JENKINS, A., HAN, C., KAUR, K., PERREN, T. and GANESAN, T. S., 2011. A prospective randomised phase II trial of thalidomide with carboplatin compared with carboplatin alone as a first-line therapy in women with ovarian cancer, with evaluation of potential surrogate markers of angiogenesis: Eur J Gynaecol Oncol Eur J Gynaecol Oncol. 32(3), 253-8
• MOHAMMED, M. Z., VYJAYANTI, V. N., LAUGHTON, C. A., DEKKER, L. V., FISCHER, P. M., WILSON, D. M., 3RD, ABBOTTS, R., SHAH, S., PATEL, P. M., HICKSON, I. D. and MADHUSUDAN, S., 2011. Development and evaluation of human AP endonuclease inhibitors in melanoma and glioma cell lines: Br J Cancer Br J Cancer. 104(4), 653-63
• ZHANG, JIHONG, STEVENS, MALCOLM F G, LAUGHTON, CHARLES A, MADHUSUDAN, SRINIVASAN and BRADSHAW, TRACEY D, 2010. Acquired resistance to temozolomide in glioma cell lines: molecular mechanisms and potential translational applications. Oncology. 78(2), 103-14
• ZHANG, J., STEVENS, M. F., LAUGHTON, C. A., MADHUSUDAN, S. and BRADSHAW, T. D., 2010. Acquired resistance to temozolomide in glioma cell lines: molecular mechanisms and potential translational applications: Oncology Oncology. 78(2), 103-14
• VALLE, J., WASAN, H., PALMER, D. H., CUNNINGHAM, D., ANTHONEY, A., MARAVEYAS, A., MADHUSUDAN, S., IVESON, T., HUGHES, S., PEREIRA, S. P., ROUGHTON, M., BRIDGEWATER, J. and A. B. C. TRIAL INVESTIGATORS, 2010. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer: N Engl J Med N Engl J Med. 362(14), 1273-81
• MALHOTRA, S., WOOD, J., MANSY, T., SINGH, R., ZAITOUN, A. and MADHUSUDAN, S., 2010. Intrahepatic sarcomatoid cholangiocarcinoma: J Oncol J Oncol. 2010, 701476
• HALLIDAY, V., KIERCZUK, G., MADHUSUDAN, S., PARSONS, S. and WILCOCK, A., 2010. Screening for malnutrition: implications for upper gastrointestinal cancer services: J Surg Oncol J Surg Oncol. 102(5), 543-4
• GOSSAGE, L., ZAITOUN, A., FAREED, K. R., TURLEY, H., ALOYSIUS, M., LOBO, D. N., HARRIS, A. L. and MADHUSUDAN, S., 2010. Expression of key hypoxia sensing prolyl-hydroxylases PHD1, -2 and -3 in pancreaticobiliary cancer: Histopathology Histopathology. 56(7), 908-20
• FAREED, K. R., AL-ATTAR, A., SOOMRO, I. N., KAYE, P. V., PATEL, J., LOBO, D. N., PARSONS, S. L. and MADHUSUDAN, S., 2010. Tumour regression and ERCC1 nuclear protein expression predict clinical outcome in patients with gastro-oesophageal cancer treated with neoadjuvant chemotherapy: Br J Cancer Br J Cancer. 102(11), 1600-7
• ABBOTTS, R. and MADHUSUDAN, S., 2010. Human AP endonuclease 1 (APE1): from mechanistic insights to druggable target in cancer: Cancer Treat Rev Cancer Treat Rev. 36(5), 425-35
• FAREED, K. R., KAYE, P., SOOMRO, I. N., ILYAS, M., MARTIN, S., PARSONS, S. L. and MADHUSUDAN, S., 2009. Biomarkers of response to therapy in oesophago-gastric cancer: Gut Gut. 58(1), 127-43
• FAREED, K. R., ILYAS, M., KAYE, P. V., SOOMRO, I. N., LOBO, D. N., PARSONS, S. L. and MADHUSUDAN, S., 2009. Tumour regression grade (TRG) analyses in patients with resectable gastro-oesophageal adenocarcinomas treated with platinum-based neoadjuvant chemotherapy: Histopathology Histopathology. 55(4), 399-406
• ALOYSIUS, M. M., LOBO, D. N., ROWLANDS, B. J., MADHUSUDAN, S., ILYAS, M. and ZAITOUN, A. M., 2009. HER-2/Neu overexpression is a rare event in peri-ampullary cancer: assessment using the HercepTest: Histopathology Histopathology. 55(2), 236-7
• MADHUSUDAN, S. and GANESAN, T. S., 2007. Tyrosine kinase inhibitors and cancer therapy: Recent Results Cancer Res Recent Results Cancer Res. 172, 25-44
• MADHUSUDAN, S. and GANESAN, T. S., 2007. Intraperitoneal gene therapy: Cancer Treat Res Cancer Treat Res. 134, 515-24
• GOSSAGE, L. and MADHUSUDAN, S., 2007. Current status of excision repair cross complementing-group 1 (ERCC1) in cancer: Cancer Treat Rev Cancer Treat Rev. 33(6), 565-77
• GOSSAGE, L. and MADHUSUDAN, S., 2007. Cancer pharmacogenomics: role of DNA repair genetic polymorphisms in individualizing cancer therapy: Mol Diagn Ther Mol Diagn Ther. 11(6), 361-80
• MADHUSUDAN, S., SMART, F., SHRIMPTON, P., PARSONS, J. L., GARDINER, L., HOULBROOK, S., TALBOT, D. C., HAMMONDS, T., FREEMONT, P. A., STERNBERG, M. J., DIANOV, G. L. and HICKSON, I. D., 2005. Isolation of a small molecule inhibitor of DNA base excision repair: Nucleic Acids Res Nucleic Acids Res. 33(15), 4711-24
• MADHUSUDAN, S., MUTHURAMALINGAM, S. R., BRAYBROOKE, J. P., WILNER, S., KAUR, K., HAN, C., HOARE, S., BALKWILL, F. and GANESAN, T. S., 2005. Study of etanercept, a tumor necrosis factor-alpha inhibitor, in recurrent ovarian cancer: J Clin Oncol J Clin Oncol. 23(25), 5950-9
• MADHUSUDAN, S. and MIDDLETON, M. R., 2005. The emerging role of DNA repair proteins as predictive, prognostic and therapeutic targets in cancer: Cancer Treat Rev Cancer Treat Rev. 31(8), 603-17
• MADHUSUDAN, S. and HICKSON, I. D., 2005. DNA repair inhibition: a selective tumour targeting strategy: Trends Mol Med Trends Mol Med. 11(11), 503-11
• LEVITT, N. C., PROPPER, D. J., MADHUSUDAN, S., BRAYBROOKE, J. P., ECHETA, C., TE POELE, R., DAVIES, S. L., FLANAGAN, E., HICKSON, I. D., JOEL, S. and GANESAN, T. S., 2005. Pharmacokinetically guided phase I trial of topotecan and etoposide phosphate in recurrent ovarian cancer: Br J Cancer Br J Cancer. 93(1), 60-9
• BRAYBROOKE, J. P., SLADE, A., DEPLANQUE, G., HARROP, R., MADHUSUDAN, S., FORSTER, M. D., GIBSON, R., MAKRIS, A., TALBOT, D. C., STEINER, J., WHITE, L., KAN, O., NAYLOR, S., CARROLL, M. W., KINGSMAN, S. M. and HARRIS, A. L., 2005. Phase I study of MetXia-P450 gene therapy and oral cyclophosphamide for patients with advanced breast cancer or melanoma: Clin Cancer Res Clin Cancer Res. 11(4), 1512-20
• MADHUSUDAN, S., TAMIR, A., BATES, N., FLANAGAN, E., GORE, M. E., BARTON, D. P., HARPER, P., SECKL, M., THOMAS, H., LEMOINE, N. R., CHARNOCK, M., HABIB, N. A., LECHLER, R., NICHOLLS, J., PIGNATELLI, M. and GANESAN, T. S., 2004. A multicenter Phase I gene therapy clinical trial involving intraperitoneal administration of E1A-lipid complex in patients with recurrent epithelial ovarian cancer overexpressing HER-2/neu oncogene: Clin Cancer Res Clin Cancer Res. 10(9), 2986-96
• MADHUSUDAN, S. and GANESAN, T. S., 2004. Tyrosine kinase inhibitors in cancer therapy: Clin Biochem Clin Biochem. 37(7), 618-35
• MADHUSUDAN, S., FOSTER, M., MUTHURAMALINGAM, S. R., BRAYBROOKE, J. P., WILNER, S., KAUR, K., HAN, C., HOARE, S., BALKWILL, F., TALBOT, D. C., GANESAN, T. S. and HARRIS, A. L., 2004. A phase II study of etanercept (Enbrel), a tumor necrosis factor alpha inhibitor in patients with metastatic breast cancer: Clin Cancer Res Clin Cancer Res. 10(19), 6528-34
• MADHUSUDAN, S., DEPLANQUE, G., BRAYBROOKE, J. P., CATTELL, E., TAYLOR, M., PRICE, P., TSALOUMAS, M. D., MOORE, N., HUSON, S. M., ADAMS, C., FRITH, P., SCIGALLA, P. and HARRIS, A. L., 2004. Antiangiogenic therapy for von Hippel-Lindau disease: JAMA JAMA. 291(8), 943-4
• DEPLANQUE, G., MADHUSUDAN, S., JONES, P. H., WELLMANN, S., CHRISTODOULOS, K., TALBOT, D. C., GANESAN, T. S., BLANN, A. and HARRIS, A. L., 2004. Phase II trial of the antiangiogenic agent IM862 in metastatic renal cell carcinoma: Br J Cancer Br J Cancer. 91(9), 1645-50
• MADHUSUDAN, S., PROTHEROE, A., PROPPER, D., HAN, C., CORRIE, P., EARL, H., HANCOCK, B., VASEY, P., TURNER, A., BALKWILL, F., HOARE, S. and HARRIS, A. L., 2003. A multicentre phase II trial of bryostatin-1 in patients with advanced renal cancer: Br J Cancer Br J Cancer. 89(8), 1418-22
• KUENEN, B. C., TABERNERO, J., BASELGA, J., CAVALLI, F., PFANNER, E., CONTE, P. F., SEEBER, S., MADHUSUDAN, S., DEPLANQUE, G., HUISMAN, H., SCIGALLA, P., HOEKMAN, K. and HARRIS, A. L., 2003. Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma: Clin Cancer Res Clin Cancer Res. 9(5), 1648-55
• BRAYBROOKE, J. P., LEVITT, N. C., JOEL, S., DAVIS, T., MADHUSUDAN, S., TURLEY, H., WILNER, S., HARRIS, A. L. and TALBOT, D. C., 2003. Pharmacokinetic study of cisplatin and infusional etoposide phosphate in advanced breast cancer with correlation of response to topoisomerase IIalpha expression: Clin Cancer Res Clin Cancer Res. 9(13), 4682-8
• MADHUSUDAN, S. and HARRIS, A. L., 2002. Drug inhibition of angiogenesis: Curr Opin Pharmacol Curr Opin Pharmacol. 2(4), 403-14